Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Sino Biopharmaceutical ( (HK:1177) ) just unveiled an update.
Sino Biopharmaceutical announced the full acquisition of LaNova Medicines, increasing its equity stake from 4.91% to 100%, making LaNova an indirect wholly-owned subsidiary. The acquisition, valued at up to USD950.92 million, is a discloseable transaction under Hong Kong’s Listing Rules, indicating a strategic expansion in the company’s operations and market positioning.
The most recent analyst rating on (HK:1177) stock is a Buy with a HK$6.19 price target. To see the full list of analyst forecasts on Sino Biopharmaceutical stock, see the HK:1177 Stock Forecast page.
More about Sino Biopharmaceutical
Sino Biopharmaceutical is a company incorporated in the Cayman Islands, primarily engaged in the biopharmaceutical industry. It focuses on the development, production, and sale of a wide range of pharmaceutical products, with a significant market presence.
Average Trading Volume: 138,859,859
Technical Sentiment Signal: Buy
Current Market Cap: HK$106.1B
For a thorough assessment of 1177 stock, go to TipRanks’ Stock Analysis page.